Wang P, Meng Z Q, Chen Z, et al. Survival rate of pancreatic cancer in elderly patients[J]. Hepato-gastroenterology, 2008, 55(82/83): 681-686.
[2]
余一祎, 刘天舒. 晚期胰腺癌姑息性化疗进展[J]. 中国癌症杂志, 2009, 19(8): 585-589. Yu Yiyi, Liu Tianshu. Advancedin palliative chemotherapy for advanced pancreat cancer[J]. China Oncology, 2009, 19(8): 585-589.
[3]
Wust P, Hidebrandt B, Streenivasa G, et al. Hyperthermia in combined treatment of cancer[J]. Lancet Oncology, 2002, 3(8): 489-497.
[4]
Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials[J]. Journal of Clinical Oncology, 2004, 22(1): 19-22.
[5]
孙燕, 周际昌. 临床肿瘤内科学[M]. 北京: 人民卫生出版社, 1997: 45-54.Sun Yan, Zhou Jichang. Medical oncology[M]. Beijing: People's Medical Publishing House, 1997: 45-54.
[6]
张太平, 王天笑, 赵玉沛. 胰腺癌诊断和治疗的瓶颈与对策[J]. 中华消 化外科杂志, 2012, 11(1): 41-44. Zhang Taiping, Wang Tianxiao, Zhao Yupei. Challenges and strategies in diagnosis and treatment of pancreatic cancer[J]. Chinese Journal of Digestive Surgery, 2012, 11(1): 41-44.
[7]
Burris H, Moore M J, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first—line therapy for patients with advanced pancreas cancer: A randomized trial[J]. Journal of Clinical Oncology, 1997, 5(6): 2403-2413.
[8]
Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: Arandomized, multicenter, phaseⅢ trial of the Swiss Group for clinical cancer research and the central european cooperative oncology group[J]. Journal of Clinical Oncology, 2007, 25(16): 2212-2217.
Maluta S, Schaffer M, Pioli F, et al. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: An open- label comparative cohort trial[J]. Strahlentherapie and Onkologic, 2011, 187(10): 619-625.
[11]
Yasuda M, Kondo M, Kokura S, et al. Comparison of concomitant gemcitabine chemotherapy and local hyperthermia, gemcitabine monoche motherapy, and local hyperthermia monotherapy for inoerable progressive pancreatic cancer[J]. Journal of Clinical Oncology, 2008, 26(Suppl 1): 15672
[12]
Grunhagen D J, de Wilt J H, van Geel A N, et al. Isolated limb perfusion with TNF- alpha and melphalan in locally advanced soft tissue sarcomas of the extremities[J]. Recent Results in Cancer Research, 2009, 179: 257-270.
[13]
Bapat A A, Hostetter G, Von Hoff D D, et al. Perineural invasion and associated pain in pancreatic cancer[J]. Nature Reviews Cancer, 2011, 11(10): 695-707.
